ProQR Therapeutics N.V.
PRQR · XNASCIK 1612940fmd_0N2HS4N655VSZC8REDZ8EB87CAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2015 to Dec 31, 2025, 35 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 1 | 4 | 7 | 19 | 16 |
| Research and development | 32 | 31 | 30 | 46 | 38 | 42 | 51 | 25 | 36 | 45 |
| Operating income | (40) | (40) | (36) | (57) | (42) | (57) | (65) | (32) | (30) | (43) |
| Interest expense | – | – | – | 1 | 4 | 3 | 5 | 1 | 1 | 1 |
| Income before taxes | (39) | (44) | (37) | (57) | (46) | (61) | (64) | (28) | (28) | (42) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 | (0) | (0) | 0 |
| Net income from continuing operations | – | (44) | (37) | (57) | (47) | (61) | (64) | (28) | (28) | (42) |
| Net income | (39) | (44) | (37) | (56) | (47) | (61) | (64) | (28) | (28) | (42) |
| Net income to common shareholders | (39) | (44) | (37) | (56) | (47) | (61) | (64) | (28) | (28) | (42) |